首页
外语
计算机
考研
公务员
职业资格
财经
工程
司法
医学
专升本
自考
实用职业技能
登录
外语
Scientists said Thursday that a new AIDS vaccine, the first ever declared to protect a significant minority of humans against th
Scientists said Thursday that a new AIDS vaccine, the first ever declared to protect a significant minority of humans against th
admin
2011-06-24
37
问题
Scientists said Thursday that a new AIDS vaccine, the first ever declared to protect a significant minority of humans against the disease, would be studied to answer two fundamental questions: why it worked in some people but not in others, and why those infected despite vaccination got no benefit at all.
The vaccine—known as RV 144, a combination of two genetically engineered vaccines, neither of which had worked before in humans—was declared a qualified success after a six-year clinical trial on more than 16,000 volunteers in Thailand. Those who were vaccinated became infected at a rate nearly one-third lower than the others, the sponsors said Thursday morning.
"I don’t want to use a word like ’breakthrough,’ but I don’t think there’s any doubt that this is a very important result," said Dr. Anthony S. Fauci, the director of the National Institute of Allergy and Infectious Diseases, which is one of the trial’s backers. "For more than 20 years now, vaccine trials have essentially been failures," Dr. Fauci said. "Now it’s like we were groping down an unlit path, and a door has been opened. We can start asking some very important questions."
It will still, however, take years of work before a vaccine that could end the epidemic, which has killed about 25 million people, can even be contemplated. "We often talk about whether a vaccine is even possible," said Mitchell Warren, the executive director of the AIDS Vaccine Advocacy Coalition, or AVAC. "This is not the vaccine mat ends the epidemic and says, ’O.K., let’s move on to something else.’ But it’s a fabulous new step that takes us in a new direction."
In which direction is still unknown. No one—including the researchers from the United States Army, the National Institutes of Health, the Thai Ministry of Public Health and two vaccine companies that tested the vaccine—knows why the vaccine gave even its weak indicator of success.
Experts generally disdain vaccines that do not protect at least 70 to 80 percent of those getting them. And this vaccine did not lower the viral loads of people who were vaccinated but caught the virus anyway, which was baffling because even mismatched vaccines usually do that. Simply repeating the trial to confirm the results would be pointless, experts agreed. The trial, the largest AIDS vaccine trial in history, cost $105 million and followed 16,402 Thai volunteers. The men and women ages 18 to 30 were recruited from two provinces southeast of the capital, Bangkok, from the general population rather than from high-risk groups like drug injectors or sex workers. Half got six doses of two different vaccines; half were given placebos. For ethical reasons, all were offered condoms, taught how to avoid infection and promised lifelong antiretroviral treatment if they got AIDS. They were then regularly tested for three years; 74 of those who got placebos became infected, but only 51 of those who got the vaccines did.
Although the difference was a mere 23 people, Col. Jerome H. Kim, a physician and the manager of the Army’s H.I.V. vaccine program, said it was statistically significant and meant that the vaccine was 31.2 percent effective. The results were surprising because both vaccines, one from the French company Sanofi-Aventis and one developed by Genentech but now licensed to Global Solutions for Infectious Diseases, a nonprofit health group, had failed when used individually. "This came out of the blue," said Chris Viehbacher, Sanofi’s chief executive. Even 31 percent protection "was at least twice as good as our own internal experts were predicting," he added. In 2004, there was so much skepticism about the trial just after it began that 22 top AIDS researchers published an editorial in Science magazine suggesting that it was a waste of money.
One conclusion from the surprising result, said Alan Bernstein, head of the Global HIV Vaccine Enterprise, an alliance of organizations pursuing a vaccine, "is that we’re not doing enough work in humans." Instead of going back to mice or monkeys, he said, different new variants on the two vaccines could be tried on a few hundred people in several countries. This vaccine was designed to combat the most common strain of the virus in Southeast Asia, so it would have to be modified for the strains circulating in Africa and the United States. Sanofi’s vaccine, Alvac-HIV, is a canarypox virus with three AIDS virus genes grafted onto it. Variations of it were tested in several countries; it was safe but not protective. The other vaccine, Aidsvax, was originally made by Genentech and contains a protein found on the surface of the AIDS virus; it is grown in a broth of hamster ovary cells. It was tested in Thai drug users in 2003 and in gay men in North America and Europe but failed. In 2007, two trials of a Merck vaccine in about 4,000 people were stopped early; it not only failed to work but for some men also seemed to increase the risk of infection.
Combining Alvac and Aidsvax was simply a hunch: if one was designed to create antibodies and the other to alert white blood cells, might they work together? One puzzling result—those who became infected had as much virus in their blood whether they got the vaccine or a placebo—suggests that RV 144 does not produce neutralizing antibodies, as most vaccines do, Dr. Fauci said. Antibodies are Y-shaped proteins formed by the body that clump onto invading viruses, blocking the surface spikes with which they attach to cells and flagging them for destruction. Instead, he theorized, it might produce "binding antibodies," which latch onto and empower effector cells, a type of white blood cell attacking the virus. Therefore, he said, it might make sense to screen all the stored Thai blood samples for binding antibodies. "The humbling prospect of this," he said, "is that we may not even be measuring the critical parameter. It may be something you don’t normally associate with protection." Dr. Lawrence Corey, the principal investigator for the HIV Vaccine Trials Network, who was not part of the RV 144 trial, said new work on weakened versions of the smallpox vaccine had produced better pox "spines" that could be substituted for the canarypox. New trials, he added, could be faster and smaller if they were done in African countries where AIDS is more common than in Thailand.
Which of the following can be used to describe the finding of RV 144?
选项
A、unexpected
B、expected
C、controversial
D、insignificant
答案
A
解析
此题是事实题。由第十段可知,RV144是凭着直觉被发现的,因此是意料之外的。
转载请注明原文地址:https://kaotiyun.com/show/q8YO777K
0
专业英语八级
相关试题推荐
Doyourememberallthoseyearswhenscientistsarguedthatsmokingwouldkillusbutthedoubtersinsistedthatwedidn’tknow
Doyourememberallthoseyearswhenscientistsarguedthatsmokingwouldkillusbutthedoubtersinsistedthatwedidn’tknow
Doyourememberallthoseyearswhenscientistsarguedthatsmokingwouldkillusbutthedoubtersinsistedthatwedidn’tknow
Doyourememberallthoseyearswhenscientistsarguedthatsmokingwouldkillusbutthedoubtersinsistedthatwedidn’tknow
Doyourememberallthoseyearswhenscientistsarguedthatsmokingwouldkillusbutthedoubtersinsistedthatwedidn’tknow
BaruchSpinozawasaDutchphilosopherandreligiousthinkerwhowasbornonNovember24,1632inAmsterdam.HisfamilywasSpan
DreiserisgenerallyregardedasthemostsignificantAmericanwriteroftheschoolknownas______.
HarryTrumandidn’tthinkhissuccessorhadtherighttrainingtobepresident."PoorIke---itwon’tbeabitliketheArmy,"
HowtoConductEmploymentInterviewsGenerallyspeaking,thepurposeofemploymentinterviewsarethree-fold:a.tomatchac
随机试题
在Excel的单个文件夹中选中多个相邻的文件时,应单击序列中的第一个文件名后,按住()键,再单击序列最后的文件即可。
男性,16岁,3天来左膝关节肿胀。自幼于外伤后易出血不止。查体:皮肤黏膜未见出血及紫癜,出血时间2分钟;凝血时间30分钟,凝血酶原时间正常,疾病分类应为( )。
下列关于药源性疾病的防治,不恰当的是()。
高聚物改性沥青防水卷材采用条粘法施工,每幅卷材两边的粘贴宽度不应小于()mm。
共有人将自己存于共有物的份额分割出去是()。
投资基金主要通过向投资者发行受益凭证(基金份额),将社会上的资金集中起来,交由()投资于各种资产,实现保值增值。
根据以下资料,回答106~110题。据统计,全球讲英语的人口达17亿,说英语的国家国内生产总值占全球的40%,全世界半数以上的科技书刊和译著都用英语,全球开设国际广播电台的86个国家中,只有8个没有英语,互联网上80%以上的网页使用英文;而开设汉语
某研究者提出一个假想:海马部位可能与复杂认知加工有关,与简单认知加工无关。为此,他进行了如下实验:随机选取30只白鼠,切除海马,让其中一半学习简单迷津,另一半学习复杂迷津。在白鼠练习迷津过程中,简单组10次以内就出现完全正确的情况,而复杂组学习30次以后才
以下行为中,属于侵犯注册商标专用权行为的是()。
在面向对象方法中,______描述的是具有相似属性与操作的一组对象。
最新回复
(
0
)